COMMENTARY

MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”

June 28, 2016
The “sakigake” pricing premium introduced in April was hailed by the pharma industry as something that would improve predictability, because it links drug reviews and reimbursement prices by giving a premium to products designated under the sakigake fast-track review pathway.…

To read the full story

Related Article

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Takashi Ebisawa

On January 8, Japan’s biggest-ever outbound acquisition is expected to come to fruition, with London-listed Shire coming under the wing of Takeda Pharmaceutical. The Japanese major is paying £46 billion, or about 7 trillion yen, for the cash-and-stock deal, and…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…